Moxifloxacine Teva (Moxifloxacin)

Moxifloxacin blocks bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes required for DNA replication and transcription. This inhibition prevents bacterial cells from reproducing, leading to bacterial death and resolution of the infection.

The dosage regimen for Moxifloxacine Teva is determined by the prescribing clinician based on the specific infection, patient characteristics, and local guidelines. Patients should follow the prescriber’s instructions and not alter the dose on their own.

The pregnancy safety category for moxifloxacin is not definitively established. It should be used during pregnancy or lactation only when the potential benefit justifies the potential risk to the fetus or infant, and after careful clinical assessment.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Moxifloxacine Teva offers a broader spectrum against Gram‑positive organisms and better activity in respiratory infections compared with some older fluoroquinolones such as ciprofloxacin. However, safety considerations like QT prolongation and tendon risk are similar across the class, so choice depends on infection type and patient risk factors.

Store the tablets at ambient temperature, preferably below 25 °C, in the original blister pack or container. Protect them from moisture, excessive heat, and direct sunlight to maintain potency throughout the shelf life.

Moxifloxacine Teva is taken orally, usually with a full glass of water. It can be taken with or without food, but patients should avoid concurrent intake of antacids containing magnesium or aluminum, which may interfere with absorption.

Serious adverse events include tendon rupture or tendinitis, QT interval prolongation that may lead to arrhythmias, severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome, Clostridioides difficile‑associated colitis, and hepatic or peripheral nerve toxicity.

Patients with a known hypersensitivity to moxifloxacin or any fluoroquinolone should avoid the drug. It is also contraindicated in individuals with a history of tendon disorders related to fluoroquinolone use, those with significant QT prolongation, and patients with uncontrolled epilepsy.